Interview with Dan Brown , Managing Director, Genzyme Australia
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
Address: PO Box 282 North Ryde B/C NSW 1670,Australia
Tel: -13819
Genzyme is one of the world’s leading biotechnology companies. Its more than 11,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.
Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2008 revenues of $4.6 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in 100 countries.
Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was chosen in 2007 to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
Genetics Diseases, Cardiometabolic and Renal, Oncology, Orthopaedics/Biosurgical Specialties, Transplant, Genetics/Diagnostics
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
See our Cookie Privacy Policy Here
